CASE REPORTS

Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations

B F O’Donnell, I S Foulds

A patient with chronic glaucoma and a history of contact allergic dermatitis to topical ophthalmic β adrenergic blocking drugs developed persistent ocular symptoms despite avoidance of β blockers. He was further investigated for possible allergy to pilocarpine.

Case report

A 70-year-old man presented with a persistent itch involving his eyes and a stinging and burning sensation aggravated by instillation of his pilocarpine eye drops. The patient had a long history of glaucoma and had bilateral trabeculectomies carried out in 1978. He still required therapy and had been treated with β blockers and pilocarpine since 1984. Treatment with β blockers had been discontinued owing to the development of contact allergic dermatitis which apparently developed sequentially to timolol, betaxolol, and metipranolol as described previously. Examination revealed periorbital oedema with erythema and swelling of the lid margins. There was no evidence of conjunctivitis. Previous patch tests with the European standard series, a preservative series, a face and eye series, a contact lens series, and pilocarpine 4% eyedrop had shown a plus/minus reaction to benzalkonium chloride and a plus/minus reaction to pilocarpine eyedrops which contained benzalkonium chloride as a preservative. Treatment was changed to unpreserved pilocarpine eyedrops, and his eyelids treated with a mild topical corticosteroid preparation. After initial improvement in the appearance and swelling of the eyelids the patient re-presented with a recurrence of the burning and stinging sensation of his eyes.

Patch testing with unpreserved pilocarpine (Minims 1%, 2%, and 4%) was negative at 2 and 4 days. Subcutaneous and intradermal testing with unpreserved pilocarpine 4% was negative at 2, 4, and 7 days, making delayed hypersensitivity unlikely. However, prick tests showed a positive reaction with the development of a 10×10 mm weal at 10–30 minutes. Prick tests in seven controls (three atopic, four non-atopic) resulted in small weals measuring up to 3 mm in diameter (four controls), or erythema only (three controls). We therefore considered that the reaction seen in our patient was significant. Pilocarpine was discontinued and substituted with levobunolol hydrochloride. The patient’s ocular and periocular symptoms improved dramatically, and his intraocular pressure was 15 mm Hg in both eyes.

<table>
<thead>
<tr>
<th>β blocker</th>
<th>Other β blockers tested</th>
<th>Cross sensitisation</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Timolol (1)*</td>
<td>–</td>
<td>propranolol</td>
<td>5</td>
</tr>
<tr>
<td>Timolol (1)</td>
<td>–</td>
<td>practanol</td>
<td>6</td>
</tr>
<tr>
<td>Levobunolol (1)</td>
<td>–</td>
<td>timolol</td>
<td>7</td>
</tr>
<tr>
<td>Metipranolol (1)</td>
<td>–</td>
<td>atenolol</td>
<td>8</td>
</tr>
<tr>
<td>Metipranolol (5)</td>
<td>–</td>
<td>oxprenolol</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>pindolol</td>
<td></td>
</tr>
<tr>
<td>Metipranolol (1)</td>
<td>–</td>
<td>sotalol</td>
<td></td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>penbutolol</td>
<td>10</td>
</tr>
<tr>
<td>Metipranolol</td>
<td>–</td>
<td>metipranolol</td>
<td></td>
</tr>
<tr>
<td>Befunolol (1)</td>
<td>–</td>
<td>levoxbunolol</td>
<td>11</td>
</tr>
<tr>
<td>Befunolol (6)</td>
<td>–</td>
<td>levoxbunolol</td>
<td></td>
</tr>
<tr>
<td>Befunolol (3)</td>
<td>–</td>
<td>levoxbunolol</td>
<td></td>
</tr>
<tr>
<td>Befunolol (4)</td>
<td>–</td>
<td>levoxbunolol</td>
<td></td>
</tr>
<tr>
<td>Metipranolol (1)</td>
<td>–</td>
<td>levoxbunolol</td>
<td></td>
</tr>
<tr>
<td>Timolol (1)</td>
<td>–</td>
<td>levoxbunolol</td>
<td></td>
</tr>
<tr>
<td>Metipranolol</td>
<td>–</td>
<td>atenolol</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>–</td>
<td>metipranolol</td>
<td>present case</td>
</tr>
</tbody>
</table>

*Figures in parentheses indicate the number(s) of patients studied.

Comment

It may be difficult to separate the clinical diagnoses of contact dermatitis, contact conjunctivitis, and contact urticaria owing to the heightened sensitivity in the eye and the adjacent skin. Contact dermatitis affecting the periocular skin may be irritant (toxic) or allergic in nature. The conjunctiva may be involved in similar processes either alone or associated with cutaneous involvement, so-called dermatocconjunctivitis. The conjunctiva with its lymphoid tissue may be involved in all immune mechanisms. The allergic reaction is a delayed hypersensitivity response (type IV) mediated by T lymphocytes. Antigen sensitised T cells release lymphokines following secondary contact with the same antigen. Diagnosis of type IV allergy may be confirmed by relevant positive patch tests. False negative reactions occur when percutaneous absorption is inadequate, concen-
Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations

tration of the allergen is too low, or the vehicle is inappropriate. To increase sensitivity intra-cutaneous injection may be carried out. If delayed hypersensitivity is suspected the results are read at 48 and 96 hours.

Various β blocking ophthalmic preparations have been implicated in allergic contact conjunctivitis' and allergic contact dermatitis'.

(Table 1). Positive allergic reactions to more than one β blocker in the same patient have raised the question of cross sensitivity between various β blockers, which has been demonstrated for some β blockers' and not for others. It is likely that cross sensitisation exists between certain β blockers only, but the numbers reported to date are small.

Contact urticaria describes a particular reaction after contact with the skin or mucous membranes. The prototype is the weal and flare response, but a spectrum exists from pruritus only through weal and flare to a systemic reaction. The diagnosis of contact urticaria may be difficult when the eyes are involved. The weal and flare response may not be apparent and the diagnosis is suggested by the symptoms of burning or stinging rather than the signs which are more easily discernible on the skin elsewhere. Symptoms occur early, being precipitated by instillation of the offending substance into the eye.

Contact urticaria is classified into immunological, non-immunological, and unknown categories. Regardless of the mechanism, the final common pathway is probably the same and eventsuate in histamine and probably other mediators being released from mast cells. Immunologically triggered contact urticaria may involve IgE mediated hypersensitivity as indicated by a positive radioallergosorbent test (RAST). Prick or scratch tests will be positive in the affected individual and negative in healthy controls, in contrast to non-immunological contact urticaria which may be elicited in healthy asymptomatic individuals.

Sensitisation to pilocarpine is rarely noted, but a case each of allergic contact dermatitis and of allergic contact and photocontact dermatitis has been reported. Contact urticaria due to pilocarpine has not, to our knowledge, previously been reported.

Our patient is of interest because in addition to type IV hypersensitivity to three ophthalmic β blockers he developed contact urticaria to pilocarpine. He is currently using levobunolol hydrochloride to control his glaucoma without showing an adverse reaction as yet.

We are grateful to Ma E Kristininger for referring the patient, and to the following pharmaceutical companies who kindly supplied β blockers for skin testing: Alcon, Allergan, Dispera, Merck Sharp and Dohme, and Smith and Nephew.

2 Herbst RA, Maibach HI. Contact dermatitis caused by allergy to ophthalmic drugs and contact lens solutions. Contact Dermatitis 1991; 25: 305–12.

British Journal of Ophthalmology 1993; 77: 741–742

Iris cyst after traumatic implantation of an eyelash into the anterior chamber

H B Hoh, M J Menage, C Dean-Hart

Bristol Eye Hospital
H B Hoh
M J Menage
C Dean-Hart

Correspondence to:
Dr H B Hoh, Bristol Eye Hospital, Lower Maudlin Street, Bristol BS1 2LX

Accepted for publication 15 June 1993

Cilia may be passively introduced into the eye during a penetrating injury and are often well tolerated in the anterior chamber (AC). The decision to surgically remove the cilium is difficult and must be based on the individual clinical situation and the possible consequences of leaving organic material in the AC.

We report a case of late development of an implantation cyst from an intraocular cilium.

Case report

A 16-year-old male presented after striking his right eye on the corner of a cardboard box. His
Contact allergic dermatitis and contact urticaria due to topical ophthalmic preparations.

B F O'Donnell and I S Foulds

doi: 10.1136/bjo.77.11.740

Updated information and services can be found at:
http://bjo.bmj.com/content/77/11/740.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/